Xenon Pharmaceuticals Inc (XENE)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.98B
Last updated: Nov 17, 2026 at 4:40 PM ET
Xenon Pharmaceuticals Inc (XENE) Statistics
Xenon Pharmaceuticals (XENE) has a market cap of $3.98B and an enterprise value of $3.90B. Its share count is up 25.89% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 2.08% below the market cap, as cash exceeds debt.
| Market Cap | $3.98B |
|---|---|
| Enterprise Value | $3.90B |
| Latest price (Nov 17, 2026) | $38.78 |
Key Dates
The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 24, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 9, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is down 4.86% over 52 weeks and trades 3.77% below its 50-day average.
| Beta (1Y) | 0.80 |
|---|---|
| 52-Week Change | -4.86% |
| 1-Month Change | +10.55% |
| 3-Month Change | -37.77% |
| 6-Month Change | -28.25% |
| 5-Year Change | +20.10% |
| 10-Year Change | +392.24% |
| Total Return (1Y) | -4.86% |
| Total Return (3Y CAGR) | +9.62% |
| Total Return (5Y CAGR) | +5.78% |
| Return vs SPY (1Y) | -16.07% |
| Max Drawdown (1Y) | -52.80% |
| Max Drawdown (3Y) | -52.80% |
| Sharpe Ratio (1Y) | -0.07 |
| Correlation with SPY (1Y) | 0.17 |
| 50-Day Average | $40.30 |
| 200-Day Average | $52.25 |
| 52-Week Range | $33.38 to $72.66 |
| RSI (14 Days) | 47.7 |
| Average Volume (20 Days) | 1.35M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 21.19x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 21.19x |
|---|---|
| Quick Ratio | 21.19x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -37.40% over the last 12 months, against a 5-year average of -28.37%.
| Return on Equity (ROE) | -37.40% |
|---|---|
| Return on Assets (ROA) | -35.73% |
| ROE (5Y Average) | -28.37% |
| ROA (5Y Average) | -26.66% |
| ROIC (5Y Average) | -63.90% |
Scores
XENE has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 1 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Gross Profit | -$611.00K |
| Operating Income | -$465.32M |
| Pretax Income | -$429.51M |
| Net Income | -$428.73M |
| Reported EPS (TTM) | -$4.70 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 95.83% of the $1.20B in total assets.
| Cash and Equivalents | $82.56M |
|---|---|
| Total Debt | $0 |
| Net Cash | $82.56M |
| Net Cash Per Share | $0.83 |
| Working Capital | $914.76M |
| Shareholder Equity | $1.15B |
| Book Value Per Share | $11.49 |
| Total Assets | $1.20B |
| Total Liabilities | $53.49M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $1.01M of capital spending, operating cash flow left -$357.11M of free cash flow.
| Operating Cash Flow | -$356.10M |
|---|---|
| Capital Expenditures | $1.01M |
| Free Cash Flow | -$357.11M |
| FCF Per Share | -$3.69 |
| Depreciation and Amortization | $2.32M |
Trailing 12 months through Sep 30, 2026.
Growth
Revenue fell 7.36% a year over 3 years.
| Revenue Growth (3Y CAGR) | -7.36% |
|---|---|
| Revenue Growth (5Y CAGR) | -25.26% |
| Book Value Per Share Growth (2Y CAGR) | -25.60% |
| Tangible Book Per Share Growth (2Y CAGR) | -25.60% |
Dividends and Yields
XENE does not pay a dividend. Its free cash flow yield is -9.23%.
| FCF Yield | -9.23% |
|---|---|
| Buyback Yield | -21.65% |
| Shareholder Yield | -21.65% |
Analyst Forecast
Consensus estimates put revenue growth at 92.59% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +92.59% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About XENE
What is XENE's market cap?
Xenon Pharmaceuticals has a market cap of $3.98B. Its enterprise value, which adds debt and subtracts cash, is $3.90B.
How many shares of XENE are outstanding?
Xenon Pharmaceuticals has 99.77M shares outstanding. The count is up 25.89% from a year earlier.
Does XENE pay a dividend?
No. Xenon Pharmaceuticals does not pay a dividend.
How much debt does XENE have?
Xenon Pharmaceuticals has $0 of total debt and $82.56M of cash and equivalents, a net cash position of $82.56M.
XENE pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors